Screening with tampons: evaluating diagnostic accuracy for STIs, BV and HPV and assessing participant views

Tampon Innovations Ltd (a subsidiary of Daye)0 个研究点目标入组 437 人开始时间: 2024年1月2日最近更新: 2024年7月8日

适应症

试验速览

暂无简介。

•1. Individuals aged 25-65 years.
•2. People assigned female at birth (AFAB).
•3. Sexually active individuals. In this case, sexually active” is defined as having penetrative vaginal sex.
•4. Group 1 only: Confirmed HPV+ diagnosis within the past 4 weeks.
•a. UK only: Ability to upload evidence of this diagnosis to the trial ePRO system (e.g. via a screenshot of the NHS app, or similar to be reviewed by the trial team).
•5. Willingness to give informed consent and adhere to trial procedures.

•1. Previous hysterectomy or total hysterectomy with removal of cervix
•2. Known allergy or sensitivity to tampons
•3. History of TSS (both tampon-associated and non-tampon associated)
•4. Individuals who are pregnant or breastfeeding.
•5. Participation in another interventional clinical trial or use of investigational drugs in the last 30 days.
•6. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.

发起方

Tampon Innovations Ltd (a subsidiary of Daye)